Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 62

Sort by

Sort Order Select

Journal Articles

Mutated Cancer-Related Genes Detected at Diagnosis of CML and a Novel Class of Variant Associated with the Philadelphia Translocation Are Both Independent Predictors of Inferior Outcomes

Naranie Shanmuganathan, FRACP,FRCPA,MBBS, Carol Wadham, PhD, Nur Hezrin Shahrin, PhD, Daniel Thomson, PhD BSc, Jinghua Feng, PhD, Verity A Saunders, Ming Lin, Rosalie Kenyon, Rob King, Paul Wang, PhD, David M Ross, MBBS, PhD FRACP, FRCPA, David T Yeung, BSc,PhDFRACP,FRCPA,MBBS, Andreas W Schreiber, PhD, Timothy P. Hughes, MDMBBS,FRACP,FRCPA, Susan Branford, PhD

Blood (2020) 136 (Supplement 1): 46–47.

https://doi.org/10.1182/blood-2020-136962

Published: 2020

Journal Articles

RNA Splicing Defects in Cancer-Linked Genes Indicate Mutation or Focal Gene Deletion and Are Associated with TKI Resistance in CML

Naranie Shanmuganathan, MBBS FRACP FRCPA, Daniel Thomson, PhD BSc, Carol Wadham, PhD, Verity A Saunders, Nur Hezrin Shahrin, PhD, David T Yeung, PhDBSc,FRACP,FRCPA,MBBS, Hamish S Scott, PhD FFSc (RCPA), Timothy P. Hughes, MDMBBS,FRACP,FRCPA, Andreas Schreiber, Susan Branford, PhD FFSc (RCPA)

Blood (2019) 134 (Supplement_1): 662.

https://doi.org/10.1182/blood-2019-123180

Published: 2019

Journal Articles

Gene Expression Signature Predicts Deep Molecular Response (DMR) in Chronic Myeloid Leukemia (CML): An Exploratory Biomarker Analysis from ENESTnd

Jerald P. Radich, MD, Richard A. Larson, MD, Hagop M. Kantarjian, MD, Michael W. Deininger, Javier Pinilla Ibarz, MD PhD, Daniel J. DeAngelo, MD PhD, Susan Branford, PhD FFSc (RCPA), Islam Sadek, Shalini Chaturvedi, Manu Sondhi, MD PhD, Matthew Wall, Kaushal Mishra, PhD, Das Purkayastha, PhD, Alok Shrestha, Vanessa Obourn, Brian S. White, Brian J. Druker

Blood (2019) 134 (Supplement_1): 665.

https://doi.org/10.1182/blood-2019-124716

Published: 2019

Journal Articles

An RNA-Based Next Generation Sequencing (NGS) Strategy Detects More Cancer Gene Mutations Than a DNA-Based Approach for the Prediction and Assessment of Resistance in CML

Susan Branford, PhD FFSc (RCPA), Carol Wadham, PhD, Naranie Shanmuganathan, MBBS FRACP FRCPA, Daniel Thomson, PhD BSc, NUR Hezrin Shahrin, PhD, Jinghua Feng, PhD, Verity A Saunders, Wendy T Parker, PhD, Rob King, Paul Wang, PhD, Hamish S Scott, PhD FFSc (RCPA), Andreas Schreiber, PhD, Timothy P. Hughes, MDMBBS,FRACP,FRCPA

Blood (2019) 134 (Supplement_1): 2918.

https://doi.org/10.1182/blood-2019-123242

Published: 2019

Journal Articles

Pro-Active Dasatinib Dose Reduction Based on Trough Levels May Minimise Toxicity and Preserve Efficacy - Interim Analysis of the ALLG CML 12 Direct Study

Blood (2019) 134 (Supplement_1): 4150.

https://doi.org/10.1182/blood-2019-127619

Published: 2019

Journal Articles

Combination of Nilotinib and Pegylated Interferon Alfa-2B Results in High Rates of MR4.5 at 24 Months - Primary Analysis of the ALLG CML 11 Pinnacle Study

Blood (2019) 134 (Supplement_1): 2926.

https://doi.org/10.1182/blood-2019-125740

Published: 2019

Journal Articles

Familial Clustering of Hematological Malignancies: Harbingers of Wider Germline Cancer Susceptibility

Anna L Brown, PhD, Milena Babic, BMPharBio (Hons), Andreas Schreiber, Jinghua Feng, PhD, Julia Dobbins, BSc (Hons), Peer Arts, PhD, Paul Wang, PhD, Kerry Phillips, Devendra K Hiwase, MBBS, MD FRACP, FRCPA, PhD, Parvathy Venugopal, PhD MSc, BSc, Susan Branford, PhD FFSc (RCPA), Nicola Poplawski, MD, Christopher N Hahn, PhD, Hamish S Scott, PhD FFSc (RCPA)

Blood (2019) 134 (Supplement_1): 3794.

https://doi.org/10.1182/blood-2019-131642

Published: 2019

Journal Articles

Development of a Data Portal for Aggregation and Analysis of Genomics Data in Familial Platelet Disorder with Predisposition to Myeloid Malignancy - the RUNX1.DB

Anna L. Brown, PhD BSc, Mark Armstrong, MSc, David Lawrence, Paul Wang, Peer Arts, PhD, Nicolas Duployez, PharmD, PhD, Jane Churpek, MD, Kiran Tawana, MD, Erin Degelman, MSc, BSc, Georges Natsoulis, PhD, Monica L. Guzman, PhD, Mrinal M. Patnaik, MD MBBS, Akiko Shimamura, MD PhD, Alan B. Cantor, MD PhD, Tim Ripperger, MD PhD, Brigitte Schlegelberger, MD PhD, Doris Steinemann, PhD, Courtney D. DiNardo, MD MSc, Cristina Mecucci, MD PhD, Elvira DRP Velloso, MD PhD, Fabio PS Santos, MD, Marcela CA Silva, Uma Borate, MD, Shannon K. McWeeney, PhD, Grzegorz Nalepa, MD PhD, Susanne Ragg, MD PhD, Erika Mijin Kwon, PhD, Anupriya Agarwal, PhD, Stephen Langabeer, PhD, Jeffery M. Klco, MD PhD, Jun J. Yang, PhD, Cecily Forsyth, FRACP, FRCPA, MBBS, Sally Mapp, MD PhD, Helen Mar Fan, MD, Lesley Rawlings, PhD, Rachel Susman, Sue Morgan, FRACP, FRCPA, MBBS, Andrew H Wei, MBBS,PhD, Inderjeet Dokal, MD, Tom Vulliamy, Devendra K Hiwase, MBBS, MD FRACP, FRCPA, PhD, Deepak Singhal, MBBS, MD FRACP, FRCPA, Susan Branford, PhD, Elli Papaemmanuil, PhD, Jean Soulier, MDPhD, Stefan Fröhling, MD, Alwin Kramer, MD, Guy Sauvageau, MD PhD, Neil Morgan, Carolyn Owen, Csaba Bödör, PhD, Jude Fitzgibbon, Hugh Y. Rienhoff, Jr., MD, Mineo Kurokawa, MD PhD, Lucy Godley, MD PhD, Claude Preudhomme, Paul P Liu, MD PhD, Nicola Poplawski, MD, Christopher N. Hahn, PhD, Hamish S. Scott, PhD

Blood (2018) 132 (Supplement 1): 5241.

https://doi.org/10.1182/blood-2018-99-118017

Published: 2018

Journal Articles

Combination of Nilotinib and Pegylated Interferon Alfa-2b Results in High Molecular Response Rates in Chronic Phase CML: Interim Results of the ALLG CML 11 Pinnacle Study

Blood (2018) 132 (Supplement 1): 459.

https://doi.org/10.1182/blood-2018-99-110569

Published: 2018

Journal Articles

The e13a2 BCR-ABL1 Transcript Is Associated with Higher Rates of Molecular Recurrence after Treatment-Free Remission Attempts: Retrospective Analysis of the Adelaide Cohort

Naranie Shanmuganathan, MBBS, Susan Branford, PhD, Agnes S. M. Yong, MDPhD, Devendra K Hiwase, MBBS, MD FRACP, FRCPA, PhD, David T Yeung, PhDBSc,FRACP,FRCPA,MBBS, David M Ross, Timothy P. Hughes, MD

Blood (2018) 132 (Supplement 1): 1731.

https://doi.org/10.1182/blood-2018-99-111083

Published: 2018

Journal Articles

High Recombination Activating Gene (RAG) Expression and RAG Mediated Recombination Is Associated with Oncogenic Rearrangement Observed with Tyrosine Kinase Inhibitor Resistant CML

Daniel Thomson, PhD BSc, Hezrin Shahrin, PhD, Paul Wang, PhD, Carol Wadham, PhD, Timothy P. Hughes, MD MBBS, FRACP, FRCPA, Andreas Schreiber, PhD, Susan Branford, PhD

Blood (2018) 132 (Supplement 1): 3001.

https://doi.org/10.1182/blood-2018-99-111212

Published: 2018

Journal Articles

Genetic Predisposition to Therapy-Related Myeloid Neoplasm By Rare, Deleterious Germline Variants in DNA Repair Pathway and Myeloid Driver Genes

Blood (2018) 132 (Supplement 1): 1802.

https://doi.org/10.1182/blood-2018-99-117815

Published: 2018

Journal Articles

De Novo UBE2A Mutations Are Recurrently Acquired during CML Progression and Interfere with Myeloid Differentiation Pathways

Blood (2017) 130 (Supplement 1): 44.

https://doi.org/10.1182/blood.V130.Suppl_1.44.44

Published: 2017

Journal Articles

Nilotinib in Combination with Pegylated Interferon Alfa-2b for CP-CML Leads to High Molecular Response Rates: Interim Results of the Pinnacle Study

Blood (2017) 130 (Supplement 1): 2898.

https://doi.org/10.1182/blood.V130.Suppl_1.2898.2898

Published: 2017

Journal Articles

Integrative Genomics Reveals Cancer Associated Mutations Are Common at Diagnosis of CML in Patients with Poor Response to TKI Therapy

Blood (2017) 130 (Supplement 1): 251.

https://doi.org/10.1182/blood.V130.Suppl_1.251.251

Published: 2017

Journal Articles

Cumulative Incidence of Treatment-Free Remission (TFR) for Patients with Chronic Myeloid Leukemia (CML): The Adelaide Experience

Naranie Shanmuganathan, MBBS, Susan Branford, PhD, David Yeung, PhDBSc,FRACP,FRCPA,MBBS, Devendra K Hiwase, MBBS, MD FRACP, FRCPA, PhD, Agnes S. M. Yong, MDPhD, David M Ross, MBBS, PhD FRACP, FRCPA, Timothy P. Hughes, MD MBBS, FRACP, FRCPA

Blood (2017) 130 (Supplement 1): 1621.

https://doi.org/10.1182/blood.V130.Suppl_1.1621.1621

Published: 2017

Journal Articles

Long-Term Follow-up of the ALLG CML8 Twister Study of Treatment-Free Remission (TFR) in Patients with Chronic Myeloid Leukemia (CML)

David M Ross, MBBS, PhD FRACP, FRCPA, Ilaria S Pagani, PhD, Naranie Shanmuganathan, MBBS, John F Seymour, MBBS, PhD, Anthony K Mills, FRACP, FRCPA, MBBS, Robin J Filshie, PhDFRACP,FRCPA, Christopher K Arthur, MDFRACP,FRCPA,MBBS, Phuong Dang, Verity A Saunders, Jody Braley, David T Yeung, PhDBSc,FRACP,FRCPA,MBBS, Deborah L White, PhD FFSc (RCPA), Andrew P Grigg, MBBS, MD FRACP, FRCPA, Anthony P Schwarer, MD MBBS (Hons), FRACP, FRCPA, Susan Branford, PhD, Timothy P. Hughes, MD

Blood (2017) 130 (Supplement 1): 1597.

https://doi.org/10.1182/blood.V130.Suppl_1.1597.1597

Published: 2017

Journal Articles

Novel Fusion Genes at CML Diagnosis Reveal a Complex Pattern of Genomic Rearrangements and Sequence Inversions Associated with the Philadelphia Chromosome in Patients with Early Blast Crisis

Justine E Marum, PhD, Paul PS Wang, PhD, Doris Stangl, PhD, David T. Yeung, BSc, MBBS, FRACP, FRCPA, Martin C. Mueller, Christian T. Dietz, PhD, Ieuan Walker, MSc, BSc, MBBS, Nathalie Nataren, BSc, Zoe Donaldson, BSc, Wendy T Parker, PhD, David M. Ross, MBBS, PhD FRACP, FRCPA, Hamish S Scott, BSc, PhD FFSc (RCPA), FAHMS, Timothy P. Hughes, MD FRACP, FRCPA, MBBS, FAAHMS, Andreas W Schreiber, PhD, Susan Branford, PhD FFSc (RCPA)

Blood (2016) 128 (22): 1219.

https://doi.org/10.1182/blood.V128.22.1219.1219

Published: 2016

Journal Articles

Efficacy and Safety of Nilotinib 300 Mg Twice Daily (BD) in Patients with CML in Chronic Phase (CML-CP) Who Are Intolerant to Prior BCR-ABL Tyrosine Kinase Inhibitors (TKIs): Results from the Randomized, Phase IIIb E.N.E.S.Tswift Study

Devendra K Hiwase, MBBS, MD FRACP, FRCPA, PhD, Peter Tan, James D'Rozario, John Taper, MBBS FRACP FRCPA, Anthony Richard Powell, FRACP, MBBS, Ian Irving, Matthew P.F. Wright, MBBS, FRCPA, FRACP, Susan Branford, PhD FFSc (RCPA), David T. Yeung, BSc, MBBS, FRACP, FRCPA, Luke Anderson, Othon L Gervasio, Timothy P. Hughes, MD

Blood (2016) 128 (22): 5447.

https://doi.org/10.1182/blood.V128.22.5447.5447

Published: 2016

Journal Articles

Upfront Imatinib with Selective Early Switching to Nilotinib Leads to Excellent Achievement of Deep Molecular Response in Chronic Phase CML: 5 Year (Final) Analysis of the TIDEL-II Study

Blood (2016) 128 (22): 939.

https://doi.org/10.1182/blood.V128.22.939.939

Published: 2016

NARROW

Mutated Cancer-Related Genes Detected at Diagnosis of CML and a Novel Class of Variant Associated with the Philadelphia Translocation Are Both Independent Predictors of Inferior Outcomes

RNA Splicing Defects in Cancer-Linked Genes Indicate Mutation or Focal Gene Deletion and Are Associated with TKI Resistance in CML

Gene Expression Signature Predicts Deep Molecular Response (DMR) in Chronic Myeloid Leukemia (CML): An Exploratory Biomarker Analysis from ENESTnd

An RNA-Based Next Generation Sequencing (NGS) Strategy Detects More Cancer Gene Mutations Than a DNA-Based Approach for the Prediction and Assessment of Resistance in CML

Pro-Active Dasatinib Dose Reduction Based on Trough Levels May Minimise Toxicity and Preserve Efficacy - Interim Analysis of the ALLG CML 12 Direct Study

Combination of Nilotinib and Pegylated Interferon Alfa-2B Results in High Rates of MR4.5 at 24 Months - Primary Analysis of the ALLG CML 11 Pinnacle Study

Familial Clustering of Hematological Malignancies: Harbingers of Wider Germline Cancer Susceptibility

Development of a Data Portal for Aggregation and Analysis of Genomics Data in Familial Platelet Disorder with Predisposition to Myeloid Malignancy - the RUNX1.DB

Combination of Nilotinib and Pegylated Interferon Alfa-2b Results in High Molecular Response Rates in Chronic Phase CML: Interim Results of the ALLG CML 11 Pinnacle Study

The e13a2 BCR-ABL1 Transcript Is Associated with Higher Rates of Molecular Recurrence after Treatment-Free Remission Attempts: Retrospective Analysis of the Adelaide Cohort

High Recombination Activating Gene (RAG) Expression and RAG Mediated Recombination Is Associated with Oncogenic Rearrangement Observed with Tyrosine Kinase Inhibitor Resistant CML

Genetic Predisposition to Therapy-Related Myeloid Neoplasm By Rare, Deleterious Germline Variants in DNA Repair Pathway and Myeloid Driver Genes

De Novo UBE2A Mutations Are Recurrently Acquired during CML Progression and Interfere with Myeloid Differentiation Pathways

Nilotinib in Combination with Pegylated Interferon Alfa-2b for CP-CML Leads to High Molecular Response Rates: Interim Results of the Pinnacle Study

Integrative Genomics Reveals Cancer Associated Mutations Are Common at Diagnosis of CML in Patients with Poor Response to TKI Therapy

Cumulative Incidence of Treatment-Free Remission (TFR) for Patients with Chronic Myeloid Leukemia (CML): The Adelaide Experience

Long-Term Follow-up of the ALLG CML8 Twister Study of Treatment-Free Remission (TFR) in Patients with Chronic Myeloid Leukemia (CML)

Novel Fusion Genes at CML Diagnosis Reveal a Complex Pattern of Genomic Rearrangements and Sequence Inversions Associated with the Philadelphia Chromosome in Patients with Early Blast Crisis

Efficacy and Safety of Nilotinib 300 Mg Twice Daily (BD) in Patients with CML in Chronic Phase (CML-CP) Who Are Intolerant to Prior BCR-ABL Tyrosine Kinase Inhibitors (TKIs): Results from the Randomized, Phase IIIb E.N.E.S.Tswift Study

Upfront Imatinib with Selective Early Switching to Nilotinib Leads to Excellent Achievement of Deep Molecular Response in Chronic Phase CML: 5 Year (Final) Analysis of the TIDEL-II Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only